ガバペンチンの世界市場レポート 2025年

ガバペンチン市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.2％で41億2,000万米ドルに成長します。この予測期間における成長は、慢性疼痛管理に対する需要の高まり、ガバペンチン製剤の承認の増加、発展途上地域におけるヘルスケアアクセスの改善、個別化医療の重視、神経疾患の負担増などに起因しています。この期間に予想される主要動向には、ドラッグデリバリーシステムの進歩、ガバペンチンの併用療法への統合、神経因性疼痛に対する技術主導の研究開発、徐放性製剤の進歩、薬理ゲノム応用の開発などがあります。

てんかんの有病率の増加は、今後数年間のガバペンチン市場の成長を牽引すると予想されています。てんかんは、脳内の異常な電気的活動によって引き起こされる発作を繰り返す神経疾患です。てんかん患者の増加は、高齢化が進んでいることが主要原因であり、高齢化が進むと、てんかん発作を引き起こす可能性のある神経疾患のリスクが高まります。ガバペンチンは、脳内の異常な神経活動を安定化させ、てんかん発作の引き金となるシグナルを減少させることにより、てんかんの管理に役立ちます。カルシウムチャネルを標的として作用し、発作エピソードを予防します。例えば、2024年5月、米国政府機関である疾病対策予防センター（CDC）は、2022年には18歳以上の米国成人約290万人が活動性てんかんを患っていると報告しました。その結果、てんかん罹患率の増加がガバペンチン市場の拡大に寄与しています。

ガバペンチン市場の主要企業は、治療効果を向上させ、神経疾患の治療選択肢を広げるため、生物学的同等性錠剤などの新興国製剤の開発に注力しています。生物学的同等性錠剤とは、先発品と同量の有効成分を同程度の速度で血中に送り込み、同等の安全性と有効性を確保するジェネリック製剤です。例えば、2024年3月、インドの製薬会社であるStrides Pharma Science Limitedは、米国食品医薬品局（USFDA）の承認を受け、600mgと800mgの強さのガバペンチン錠USPを上市しました。この先進的なガバペンチン製剤は、改善されたバイオアベイラビリティ、正確な服用、便利な投与を提供し、より一貫した治療結果、より良い症状コントロール、長期治療における使いやすさをサポートします。ガバペンチン錠USP, 600mgは、信頼性の高い投与と臨床的に検証された有効性により、神経障害性疼痛や部分発作などの様々な神経症状を効果的に管理し、多彩な治療効果をもたらします。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、コロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のガバペンチン：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のガバペンチン市場：成長率分析
• 世界のガバペンチン市場の実績：規模と成長、2019～2024年
• 世界のガバペンチン市場の予測：規模と成長、2024～2029年、2034年
• 世界のガバペンチン：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界のガバペンチン市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ジェネリック
• ブランド
• 世界のガバペンチン市場：剤形別、実績と予測、2019～2024年、2024～2029年、2034年
• 錠剤
• カプセル
• 経口溶液
• 世界のガバペンチン市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• その他
• 世界のガバペンチン市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• てんかん
• 神経障害性疼痛
• むずむず脚症候群
• その他
• 世界のガバペンチン市場、ジェネリックのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ガバペンチン即時リリース（IR）
• ガバペンチンエクステンデッドリリース（ER）
• ガバペンチンカプセル
• ガバペンチン錠剤
• ガバペンチン経口溶液
• 世界のガバペンチン市場、ブランドのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ニューロンチン
• グラリス
• ホリザント
• その他

第7章 地域別・国別分析

• 世界のガバペンチン市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のガバペンチン市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ガバペンチン市場：競合情勢
• ガバペンチン市場：企業プロファイル
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan Inc.
  • Apotex Inc.
  • Sun Pharmaceutical Industries Ltd.

第31章 その他の大手企業と革新的企業

• Aurobindo Pharma Limited
• Cipla Limited
• Lupin Limited
• Zydus Lifesciences Limited
• Glenmark Pharmaceuticals Limited
• Torrent Pharmaceuticals Ltd.
• Ipca Laboratories Private Limited
• Granules India Limited
• Medley Pharmaceuticals Limited
• Wockhardt Limited
• Epic Pharma LLC
• Healing Pharma India Pvt. Ltd.
• Rochem International Inc.
• Accord Healthcare Limited
• Strides Pharma Science Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• ガバペンチン市場、2029年：新たな機会を提供する国
• ガバペンチン市場、2029年：新たな機会を提供するセグメント
• ガバペンチン市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Gabapentin is a prescription drug primarily used to manage nerve pain, epilepsy, and restless legs syndrome. It works by affecting nerve signals and brain chemicals to control seizures and alleviate nerve pain. It is commonly prescribed for nerve-related conditions such as pain from shingles and diabetic neuropathy. Gabapentin helps stabilize brain activity and decrease abnormal nerve excitability.

Gabapentin is available in both generic and branded forms. Generic versions contain the same active ingredients and dosages as branded ones, offering a more cost-effective but equally effective treatment option. It comes in multiple dosage forms, including tablets, capsules, and oral solutions, and is distributed through various channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others. Its primary applications include treatment for epilepsy, neuropathic pain, restless legs syndrome, and additional related conditions.

The gabapentin market research report is one of a series of new reports from The Business Research Company that provides gabapentin market statistics, including the gabapentin industry global market size, regional shares, competitors with the gabapentin market share, detailed gabapentin market segments, market trends, opportunities, and any further data you may need to thrive in the gabapentin industry. This gabapentin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gabapentin market size has grown strongly in recent years. It will grow from $2.78 billion in 2024 to $3.01 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth during the historic period can be attributed to the rising prevalence of epilepsy, an increase in cases of neuropathic pain, heightened awareness of neurological disorders, a growing elderly population, and the expanded use of generic anticonvulsant medications.

The gabapentin market size is expected to see strong growth in the next few years. It will grow to $4.12 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to the rising demand for chronic pain management, increasing approvals of gabapentin formulations, improved healthcare access in developing regions, a greater emphasis on personalized medicine, and the growing burden of neurological disorders. Key trends expected during this period include advancements in drug delivery systems, the integration of gabapentin into combination therapies, technology-driven R&D for neuropathic pain, progress in extended-release formulations, and developments in pharmacogenomics applications.

The rising prevalence of epilepsy is expected to drive the growth of the gabapentin market in the coming years. Epilepsy is a neurological disorder marked by recurring seizures caused by abnormal electrical activity in the brain. The increase in epilepsy cases is largely attributed to the growing aging population, as advancing age heightens the risk of neurological conditions that can lead to seizures. Gabapentin helps manage epilepsy by stabilizing abnormal nerve activity in the brain and reducing signals that trigger seizures. It acts by targeting calcium channels to prevent seizure episodes. For example, in May 2024, the Centers for Disease Control and Prevention (CDC), a U.S. government agency, reported that around 2.9 million U.S. adults aged 18 and older were living with active epilepsy in 2022, reflecting a 1.08% increase compared to 2021. As a result, the growing incidence of epilepsy is contributing to the expansion of the gabapentin market.

Leading companies in the gabapentin market are concentrating on developing advanced formulations, such as bioequivalent tablets, to improve therapeutic efficacy and broaden treatment options for neurological disorders. Bioequivalent tablets are generic formulations that deliver the same amount of active ingredient into the bloodstream at the same rate and extent as the branded version, ensuring equivalent safety and effectiveness. For example, in March 2024, Strides Pharma Science Limited, an India-based pharmaceutical company, launched Gabapentin Tablets USP in 600 mg and 800 mg strengths following approval from the United States Food & Drug Administration (USFDA), aiming to expand its neurology portfolio in the U.S. market. This advanced gabapentin formulation offers improved bioavailability, accurate dosing, and convenient administration, supporting more consistent therapeutic results, better symptom control, and ease of use in long-term treatment. Gabapentin Tablets USP, 600 mg, provide versatile therapeutic benefits, effectively managing various neurological conditions such as neuropathic pain and partial seizures through dependable dosing and clinically validated efficacy.

In September 2023, Adalvo, a Malta-based pharmaceutical company, partnered with Lotus Pharmaceutical to improve lives by providing accessible and innovative neurological treatments. This collaboration focuses on introducing a convenient, once-daily treatment for postherpetic neuralgia through the launch of Gabapentin ER in South Korea. The initiative aims to address unmet medical needs while strengthening their presence in the neurology market. Lotus Pharmaceutical, based in Taiwan, is the manufacturer of gabapentin extended-release tablets.

Major players in the gabapentin market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan Inc., Apotex Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., Ipca Laboratories Private Limited, Granules India Limited, Medley Pharmaceuticals Limited, Wockhardt Limited, Epic Pharma LLC, Healing Pharma India Pvt. Ltd., Rochem International Inc., Accord Healthcare Limited, Strides Pharma Science Limited, Ascend Laboratories LLC.

North America was the largest region in the gabapentin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gabapentin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gabapentin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gabapentin market consists of sales of gabapentin immediate-release, gabapentin extended-release, and oral solution. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gabapentin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gabapentin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gabapentin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gabapentin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Generic; Branded
• 2) By Dosage Form: Tablet; Capsule; Oral Solution
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• 4) By Application: Epilepsy; Neuropathic Pain; Restless Legs Syndrome; Other Applications
• Subsegments:
• 1) By Generic: Gabapentin Immediate Release (IR); Gabapentin Extended Release (ER); Gabapentin Capsules; Gabapentin Tablets; Gabapentin Oral Solution
• 2) By Branded: Neurontin; Gralise; Horizant; Other Branded Formulations
• Companies Mentioned: Pfizer Inc.; Teva Pharmaceutical Industries Ltd.; Mylan Inc.; Apotex Inc.; Sun Pharmaceutical Industries Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gabapentin Market Characteristics

3. Gabapentin Market Trends And Strategies

4. Gabapentin Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Gabapentin Growth Analysis And Strategic Analysis Framework

• 5.1. Global Gabapentin PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Gabapentin Market Growth Rate Analysis
• 5.4. Global Gabapentin Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Gabapentin Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Gabapentin Total Addressable Market (TAM)

6. Gabapentin Market Segmentation

• 6.1. Global Gabapentin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic
• Branded
• 6.2. Global Gabapentin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablet
• Capsule
• Oral Solution
• 6.3. Global Gabapentin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
• 6.4. Global Gabapentin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epilepsy
• Neuropathic Pain
• Restless Legs Syndrome
• Other Applications
• 6.5. Global Gabapentin Market, Sub-Segmentation Of Generic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gabapentin Immediate Release (IR)
• Gabapentin Extended Release (ER)
• Gabapentin Capsules
• Gabapentin Tablets
• Gabapentin Oral Solution
• 6.6. Global Gabapentin Market, Sub-Segmentation Of Branded, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Neurontin
• Gralise
• Horizant
• Other Branded Formulations

7. Gabapentin Market Regional And Country Analysis

• 7.1. Global Gabapentin Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Gabapentin Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gabapentin Market

• 8.1. Asia-Pacific Gabapentin Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gabapentin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Gabapentin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Gabapentin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gabapentin Market

• 9.1. China Gabapentin Market Overview
• 9.2. China Gabapentin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Gabapentin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Gabapentin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gabapentin Market

• 10.1. India Gabapentin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Gabapentin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Gabapentin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gabapentin Market

• 11.1. Japan Gabapentin Market Overview
• 11.2. Japan Gabapentin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Gabapentin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Gabapentin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gabapentin Market

• 12.1. Australia Gabapentin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Gabapentin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Gabapentin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gabapentin Market

• 13.1. Indonesia Gabapentin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Gabapentin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Gabapentin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gabapentin Market

• 14.1. South Korea Gabapentin Market Overview
• 14.2. South Korea Gabapentin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Gabapentin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Gabapentin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gabapentin Market

• 15.1. Western Europe Gabapentin Market Overview
• 15.2. Western Europe Gabapentin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Gabapentin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Gabapentin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gabapentin Market

• 16.1. UK Gabapentin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Gabapentin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Gabapentin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gabapentin Market

• 17.1. Germany Gabapentin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Gabapentin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Gabapentin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gabapentin Market

• 18.1. France Gabapentin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Gabapentin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Gabapentin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gabapentin Market

• 19.1. Italy Gabapentin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Gabapentin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Gabapentin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gabapentin Market

• 20.1. Spain Gabapentin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Gabapentin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Gabapentin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gabapentin Market

• 21.1. Eastern Europe Gabapentin Market Overview
• 21.2. Eastern Europe Gabapentin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Gabapentin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Gabapentin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gabapentin Market

• 22.1. Russia Gabapentin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Gabapentin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Gabapentin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gabapentin Market

• 23.1. North America Gabapentin Market Overview
• 23.2. North America Gabapentin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Gabapentin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Gabapentin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gabapentin Market

• 24.1. USA Gabapentin Market Overview
• 24.2. USA Gabapentin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Gabapentin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Gabapentin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gabapentin Market

• 25.1. Canada Gabapentin Market Overview
• 25.2. Canada Gabapentin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Gabapentin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Gabapentin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gabapentin Market

• 26.1. South America Gabapentin Market Overview
• 26.2. South America Gabapentin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Gabapentin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Gabapentin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gabapentin Market

• 27.1. Brazil Gabapentin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Gabapentin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Gabapentin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gabapentin Market

• 28.1. Middle East Gabapentin Market Overview
• 28.2. Middle East Gabapentin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Gabapentin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Gabapentin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gabapentin Market

• 29.1. Africa Gabapentin Market Overview
• 29.2. Africa Gabapentin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Gabapentin Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Gabapentin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gabapentin Market Competitive Landscape And Company Profiles

• 30.1. Gabapentin Market Competitive Landscape
• 30.2. Gabapentin Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Mylan Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Apotex Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Gabapentin Market Other Major And Innovative Companies

• 31.1. Aurobindo Pharma Limited
• 31.2. Cipla Limited
• 31.3. Lupin Limited
• 31.4. Zydus Lifesciences Limited
• 31.5. Glenmark Pharmaceuticals Limited
• 31.6. Torrent Pharmaceuticals Ltd.
• 31.7. Ipca Laboratories Private Limited
• 31.8. Granules India Limited
• 31.9. Medley Pharmaceuticals Limited
• 31.10. Wockhardt Limited
• 31.11. Epic Pharma LLC
• 31.12. Healing Pharma India Pvt. Ltd.
• 31.13. Rochem International Inc.
• 31.14. Accord Healthcare Limited
• 31.15. Strides Pharma Science Limited

32. Global Gabapentin Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gabapentin Market

34. Recent Developments In The Gabapentin Market

35. Gabapentin Market High Potential Countries, Segments and Strategies

• 35.1 Gabapentin Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Gabapentin Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Gabapentin Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer